Table 2. Adverse Events of Ivosidenib (N = 179).
| All grades, no. (%) | ≥ Grade 3, no. (%) | |
|---|---|---|
| Hematologic event | ||
| Leukocytosis | 68 (38) | 15 (8) |
| Differentiation syndrome | 34 (19) | 23 (13) |
| Gastrointestinal | ||
| Diarrhea | 60 (34) | 4 (2) |
| Nausea | 56 (31) | 1 (1) |
| Mucositis | 51 (28) | 6 (3) |
| Constipation | 35 (20) | 1 (1) |
| Vomiting | 31 (18) | 2 (1) |
| Abdominal pain | 29 (16) | 2 (1) |
| Decreased appetite | 33 (18) | 3 (2) |
| General disorders | ||
| Fatigue | 69 (39) | 6 (3) |
| Edema | 57 (32) | 2 (1) |
| Pyrexia | 41 (23) | 2 (1) |
| Chest pain | 29 (16) | 5 (3) |
| Rash | 46 (26) | 4 (2) |
| Cardiac | ||
| QT prolongation | 46 (26) | 18 (10) |
| Hypotension | 22 (12) | 7 (4) |
| Electrolyte abnormalities | ||
| Tumor lysis syndrome | 14 (8) | 11 (6) |
| Musculoskeletal | ||
| Arthralgia | 64 (36) | 8 (4) |
| Myalgia | 33 (18) | 1 (1) |
| Neurologic | ||
| Headache | 28 (16) | 0 |
| Neuropathy | 21 (12) | 2 (1) |
| Respiratory | ||
| Cough | 40 (22) | 1 (< 1) |
| Dyspnea | 59 (33) | 16 (9) |
| Pleural effusion | 23 (13) | 5 (3) |
Note. Information from DiNardo et al. (2017).